The Pithampur-based pharmaceutical formulations company has moved two important pieces into place. One is a new plant building that began running in mid-September, with more work still underway on a separate section. The other is a fresh advisory arrangement aimed at helping it look beyond its home market and consider new sources of capital. Investors will want to see how these steps sit alongside its latest quarterly numbers and what the timeline looks like, since several approvals are still pending.
Shares of Quest Laboratories Ltd are trading at Rs. 83.00, down 3.21 percent on Tuesday. The stock touched the intraday high of Rs. 83.60 after opening at Rs. 83.60 before slipping to a low of Rs. 83.00. The company commands a market capitalization of Rs. 136.01 crore.
New Building Is Running, Injection Section Is Next
Quest Laboratories Limited told the National Stock Exchange on 28 September 2026 that the first phase of its plant expansion at Pithampur is complete. A new building of about 12,000 sq. ft., fitted with a 3,000 kg goods lift, has been operational since 16 September 2026. It houses a finished goods warehouse on the ground floor, a blister line with a packing area on the first, a quality control section on the second, and a service area on the third. Civil work for the Phase-II injection section was also finished in September.
The clean room and its utilities are still being installed, the injection machines are expected by the end of December 2026, and trial runs are planned for January to February 2027. On the same day, the company said it has started a strategic advisory collaboration with Niraga Capitals Private Limited to support growth, business development and corporate development.
What the New Block and the New Adviser Could Mean for Quest
The expansion will create square footage that will benefit the company’s most productive lines by far. As of 31 March 2026, inventory was Rs.38.62 crore, compared to Rs.21.37 crore a year ago. Thus, additional warehouse space is required, but even more significantly, a larger quality control section is needed for the broader range of products. The greatest need is in the injection segment, where management’s intention to target domestic and export markets with vials, ampoules, and dry injection lines can be expected to generate significant incremental revenues. However, this requires the installation of the necessary equipment, which is dependent on the delivery of machines and the completion of other preparations before trials can begin.
The arrangement with Niraga Capitals is purely advisory, and Quest is responsible for all operational tasks and statutory requirements. The areas of exports, foreign collaborations, institutional business, raising capital, and potential acquisitions falls under this category. The terms of the arrangement, including any expenses, share offerings, or acquisition terms, were not disclosed.
In addition, any transaction must be approved by the board of directors, shareholders, and regulators and must undergo the appropriate due diligence process. It should also be noted that investors are likely to focus on the footnotes in the auditor’s report, as well as the company’s operating cash flow. For example, cash flow from operations in FY26 was -10.72 crore, and the auditor’s report contains a separate emphasis-of-matter paragraph regarding inventory.
Financial Performance
Looking at the quarterly results of Quest Laboratories Limited, the company’s standalone revenue from operations declined by 30.2 percent YoY, from Rs. 46.45 crore in Q4 FY25 to Rs. 32.40 crore in Q4 FY26, and grew by 5.9 percent QoQ from Rs. 30.61 crore in Q3 FY26.
Quest Laboratories Limited reports a single business segment and did not give a quarterly product split. In its FY25 investor presentation, tablets made up 64 percent of revenue, ORS powder 10 percent, liquid syrups and suspensions 9 percent each, and ointments 8 percent.
In Q4 FY26, the company’s net profit increased by 48.2 percent YoY, reaching Rs. 2.87 crore compared to Rs. 1.94 crore during the same period last year. As compared to Q3 FY26, the net profit has decreased by 28.7 percent, from Rs. 4.03 crore.
The basic earnings per share increased by 47.5 percent and stood at Rs. 1.74 as against Rs. 1.18 recorded in the same quarter in the previous year, FY25.
India’s Pharma Backdrop Still Works in Quest’s Favour
Quest is expanding at a time when India’s pharmaceutical sector has strong tailwinds. Its own investor presentation, citing an EY report, puts the domestic market at about US 49 billion in 2022 and projects US 450 billion by 2047. The same document says India supplies roughly 20 percent of global generic drugs by volume, and that pharmaceutical exports reached US$27.9 billion in FY24.
Low manufacturing costs and government support, including the PLI scheme and schemes for smaller manufacturers, add to that picture. For a mid-sized formulation maker, more capacity, injectables and export tie-ups fit this demand. The gains will still depend on execution, regulatory approvals and global market conditions, and these figures are industry estimates that could change.
Company Overview
Quest Laboratories Limited, based in Pithampur, Madhya Pradesh, manufactures pharmaceutical formulations, including tablets, syrups, dry syrups, ORS powders, ointments and external liquids. Incorporated in 1998 and listed on NSE SME in 2024, it sells through franchise distribution, government tenders and merchant exports. It holds approvals for over 1,300 formulations and is now adding capsule and injectable lines to its portfolio.